GlassScriptPhysician profile
Kristina N Johnson
NPI 1841426707
$15,530.26
in general payments reported to CMS, 2019-2025
65 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,852 · 2020: $1,949 · 2021: $2,304 · 2022: $2,382 · 2023: $2,284 · 2024: $2,405 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,042.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,548.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,545.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,493.12 | 2020-2025 | |
| Lilly USA, LLC | $1,127.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $922.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $859.45 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.64 | 2019-2025 | Jardiance |
| Amgen INC. | $495.57 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $460.59 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $419.44 | 2021-2025 | Rexulti |
| Esperion Therapeutics, INC. | $419.18 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $362.79 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.52 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $264.36 | 2021-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $252.44 | 2022-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.